Joseph Y. Chang - 01 Jun 2022 Form 4 Insider Report for NU SKIN ENTERPRISES, INC. (NUS)

Role
Chief Scientific Officer
Signature
/s/ Gregory Belliston as Attorney-in-Fact for Joseph Y. Chang
Issuer symbol
NUS
Transactions as of
01 Jun 2022
Net transactions value
-$254,978
Form type
4
Filing time
02 Jun 2022, 18:15:37 UTC
Previous filing
03 Mar 2022
Next filing
20 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUS Class A Common Stock Options Exercise $490,080 +16,000 +70% $30.63 38,957 01 Jun 2022 Direct
transaction NUS Class A Common Stock Sale $415,094 -8,975 -23% $46.25 29,982 01 Jun 2022 Direct F1, F2
transaction NUS Class A Common Stock Sale $329,964 -7,025 -23% $46.97 22,957 01 Jun 2022 Direct F1, F3
holding NUS Class A Common Stock 78,068 01 Jun 2022 Held in irrevocable family trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUS Employee Stock Option (Right to Buy) Options Exercise $0 -16,000 -38% $0.000000 26,600 01 Jun 2022 Class A Common Stock 16,000 $30.63 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.77 to $46.75, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.81 to $47.25, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F4 This report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F5 Currently exercisable in full.